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Objective: The purpose of this study was to examine 30-day and long-term outcomes after carotid endarterectomy (CEA)
in a contemporary series and to identify variables associated with stroke and death after CEA.
Methods: This was a retrospective review of patients undergoing an isolated CEA at a single institution between January
1989 and December 2005. Primary study end points were 30-day and long-term overall stroke, ipsilateral stroke, and
death. Secondary end points were recurrent stenosis (>70% stenosis) and reintervention. Kaplan-Meier analysis was used
to create survival curves for the long-term study end points. Multivariate models were created to identify variables
associated with the study end points.
Results: During the study period, 3014 CEAs were performed on 2644 patients (mean age, 71.0 6 8.9 years; 60.9% male;
33.5% symptomatic; 37% primary closure), with mean follow-up of 7.0 years. The 30-day ipsilateral stroke, death, and
combined ipsilateral stroke/death rates were 1.3%, 1.1%, and 2.2%, respectively. Previous ipsilateral CEA or neck
dissection for cancer (hazard ratio [HR], 3.68; P [ .0081) and symptomatic disease (HR, 2.45; P [ .0071) were
predictive of 30-day ipsilateral stroke. Stroke-free survival was 93.8% at 4 years and 86.9% at 10 years. Diabetes (HR,
1.94; P < .0001), symptomatic disease (HR, 1.75; P < .0001), female gender (HR, 1.34; P [ .035), and increasing age
(HR, 1.02; P < .0001) were predictors of long-term overall stroke. Ipsilateral stroke-free survival was 97.6% at 5 years
and 94.6% at 10 years, respectively. Contralateral occlusion (HR, 2.06; P [ .025) and symptomatic disease (HR, 1.87;
P [ .003) were predictors of ipsilateral stroke, whereas antilipid therapy was protective (HR, 0.65; P [ .049). Overall
survival was 70.1% at 5 years and 42.2% at 10 years, with no difference between symptomatic and asymptomatic patients.
Although a variety of comorbidities were associated with inferior late survival, as anticipated, female gender (HR, 0.89;
P [ .016) and lipid-lowering therapy (HR, 0.69; P < .0001) were protective. Reintervention was 3.4% at 5 years and
6.6% at 10 years, with primary closure (vs patch angioplasty/eversion) increasing the risk of reintervention (HR, 1.72;
P [ .007).
Conclusions: CEA has favorable perioperative and long-term clinical and anatomic outcomes with respect to its goal of
stroke prevention for symptomatic and asymptomatic patients. Adjuvant medical therapy (antilipid) has increased overall
and ipsilateral stroke-free survival. (J Vasc Surg 2014;59:944-9.)Randomized controlled trials have shown that carotid
endarterectomy (CEA) signiﬁcantly reduces the risk of
subsequent stroke from carotid artery stenosis for both
symptomatic1-3 and asymptomatic4-6 patients. However,
due to patient inclusion criteria or claims that medical
therapy was inadequate, or both, some have questioned
whether these randomized controlled trials truly reﬂect
the real-world experience across the spectrum of patients
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://dx.doi.org/10.1016/j.jvs.2013.10.059A number of large institutional series have reported
favorable perioperative and long-term stroke-free and over-
all survival after CEA7-10 outside the conﬁnes of random-
ized trials. In a previous report detailing CEA patients
treated between 1989 and 1999, we noted a perioperative
stroke/death rate of 1.4% and a 22% reduction in the age-
adjusted and gender-adjusted incidence of any stroke
during follow-up (median follow-up period of 5.9 years).10
The overall survival in this cohort of 1897 patients was 72%
at 5 years and 45% at 10 years. Contemporary criticism of
the above-cited single-center series is that they are
outdated, and as such, fail to consider the effect of modern
adjunctive medical therapy and advances in technique such
as closure of the arteriotomy with patch angioplasty.
Accordingly, the purpose of this study was to examine
30-day and long-term outcomes after CEA in a contempo-
rary series and to identify variables associated with peri-
operative and long-term stroke and death. In addition,
we sought to determine the reintervention rate after CEA
and identify factors predictive of said outcome.
METHODS
The Massachusetts General Hospital Institutional
Review Board approved this clinical protocol.
Table I. Demographic, clinical, and intraoperative features
Characteristic Mean 6 SD or %
Age, years 71.0 6 8.9
Male 60.9
Coronary artery disease 53.9
Hypertension 81.9
COPD 13.5
Diabetes mellitus 23.6
Chronic renal insufﬁciencya 18.7
Lipid-lowering therapyb 66.4
Current smoker 22.7
Symptomatic disease 33.5
Redo CEA/neck dissectionc 4.2
Radiotherapy 2.1
Contralateral carotid occlusion 6.4
General anesthesia 96.4
Intraoperative EEG changes 20.5
Shunt use 32
Closure
Primary closured 37
Patch angioplasty 52
Eversion CEA 10.9
CEA, Carotid endarterectomy; COPD, chronic obstructive pulmonary
disease; EEG, electroencephalography; SD, standard deviation.
aDeﬁned as serum creatinine >1.5 mg/dL.
bIncludes statin and nonstatin therapy.
cPrevious ipsilateral CEA or neck dissection.
dGiven study interval, routine patching was not adopted until a later period
of the study.
Table II. Independent risk factors associated with
30-day any stroke and ipsilateral stroke using logistic
regression
Variable OR (95% CI) Pa
Any stroke
Redo/neck dissection 3.23 (1.33-7.83) .0095
Contralateral occlusion 2.92 (1.34-6.38) .0073
Symptomatic disease 2.39 (1.35-4.22) .0027
Ipsilateral stroke
Redo/neck dissectionb 3.68 (1.40-9.67) 0.0081
Symptomatic disease 2.45 (1.28-4.71) 0.0071
CEA, Carotid endarterectomy; CI, conﬁdence interval; OR, odds ratio.
aAll P values are signiﬁcant (P < .05).
bRedo CEA or previous neck dissection.
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and December 2005 (chosen to ensure a minimum 5-
year follow-up), 3014 isolated CEAs were performed on
2644 patients by the Massachusetts General Hospital
Division of Vascular Surgery. Patients who underwent
concurrent procedures at the time of CEA (eg, coronary
artery bypass) were excluded from the study. Decisions
regarding the technical conduct of the operation were left
to the discretion of the individual surgeon.
Patient demographic and clinical data were collected
through a retrospective review of the hospital medical
records, as were perioperative and intraoperative factors.
Long-term stroke, restenosis, and reintervention data
were gathered by reviewing all outpatient clinic visits,
hospital admissions, carotid noninvasive studies, and rele-
vant radiologic studies. In our practice, patients are
routinely evaluated at 4 to 6 weeks after the index proce-
dure by the individual surgeon along with carotid noninva-
sive studies. Patients are then followed up annually
according to the discretion of the treating surgeon.
Long-term survival was determined through a review of
the medical record and the Social Security Death Index
when necessary.
Deﬁnitions and end points. Patients were considered
to have symptomatic disease if they had an ipsilateral
stroke, transient ischemic attack, or amaurosis fugax within
the 6 months preceding the CEA. Chronic renal insufﬁ-
ciency was deﬁned as a serum creatinine level of
>1.5 mg/dL. Antilipid treatment included statin and non-
statin therapy. Ipsilateral stroke included any stroke that
occurred on the side of the indexed carotid procedure.
The primary study end points included 30-day and
long-term any stroke, ipsilateral stroke, and death. The
secondary end point was reintervention, which included
reoperative CEA and carotid stent placement.
Statistical analysis. All statistical calculations were
performed using SAS 9.2 software (SAS Institute, Cary,
NC). Survival analysis was performed using Kaplan-Meier
life-table methods. Factors associated with 30-day stroke
and death were determined using logistic regression
models, and Cox proportional hazards models were created
for long-term outcomes of any stroke, ipsilateral stroke,
death, and reintervention. A P value of <.05 was consid-
ered statistically signiﬁcant.
RESULTS
During the study period, 3014 CEAs were performed
on 2644 patients, with a mean follow-up of 8.5 years
(range, 0-23 years) and a mean anatomic follow-up with
carotid duplex ultrasound imaging of 3.9 years (range,
0-20 years). Demographic and clinical features, as well as
intraoperative variables, are reported in Table I. In 33.5%
of patients, the CEA was for symptomatic disease, and
4.2% had undergone previous ipsilateral CEA or neck
dissection (redo CEA/neck dissection).
Perioperative outcomes. The 30-day any stroke rate
was 1.8%, and the ipsilateral stroke rate was 1.3%. The
30-day mortality rate was 1.1%, with a combined ipsilateralstroke and death rate of 2.2%. Table II reports the multi-
variate predictors of 30-day outcomes after CEA. Redo
CEA/previous neck dissection and symptomatic disease
were independent predictors of any stroke and ipsilateral
stroke at 30 days. In addition, contralateral occlusion was
a predictor of any stroke at 30 days after CEA.
Long-term outcomes. The freedom from any stroke
after CEA was 93.8% at 5 years and 86.9% at 10 years.
There was a signiﬁcant difference in long-term stroke-free
survival between symptomatic and asymptomatic patients
(82.9% vs 88.8% at 10 years; P < .0001; Fig 1). Ipsilateral
stroke-free survival was 97.6% at 5 years and 94.6% at
10 years. Similar to stroke-free survival, there was a signiﬁ-
cant difference in the freedom from ipsilateral stroke-free
Fig 1. Kaplan-Meier estimate for stroke-free survival after carotid
endarterectomy (CEA) stratiﬁed by symptom status. The P value
was determined by Mantel-Cox log-rank univariate analysis. SE,
Standard error.
Years 0 2 4 6 8 10 12 14
Symptomatic
At risk 909 550 427 308 223 158 107 65
SE 0 0.8 1 1 2 2 2 3
Asymptomatic
At risk 1880 1269 1013 679 457 299 195 95
SE 0 0.4 0.5 0.7 0.9 1 1 2
Fig 2. Kaplan-Meier estimate for ipsilateral stroke-free survival
after carotid endarterectomy (CEA) stratiﬁed by symptom status.
The P value was determined by Mantel-Cox log-rank univariate
analysis. SE, Standard error.
Years 0 2 4 6 8 10 12 14
Symptomatic
At risk 909 560 437 319 233 165 112 66
SE 0 0.6 0.7 0.7 1 1 2 2
Asymptomatic
At risk 1880 127 1026 697 472 312 202 100
SE 0 0.3 0.3 0.4 0.5 0.8 0.9 1
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(92.2% vs 95.7% at 10 years; P ¼ .0008; Fig 2). The long-
term survival after CEA was 70.1% at 5 years and 42.2% at
10 years, with no difference between symptomatic and
asymptomatic patients (Fig 3).
Table III reports the multivariate predictors of long-
term outcomes after CEA. Symptomatic disease was
a predictor of any stroke and ipsilateral stroke. In addition,
diabetes, female gender, and advanced age were predictors
of long-term stroke, whereas contralateral occlusion was
a predictor of long-term ipsilateral stroke. Chronic obstruc-
tive pulmonary disease, diabetes, coronary artery disease,
and advanced age decreased long-term survival after
CEA. Although female gender was predictive of long-
term stroke, it was associated with increased survival after
CEA. Lipid-lowering therapy improved ipsilateral stroke-
free survival and overall survival after CEA.
The reintervention rate after CEA was 3.4% at 5 years
and 6.6% at 10 years, with no difference in between symp-
tomatic and asymptomatic patients. Table III reports the
independent predictors of recurrent stenosis and reinter-
vention after CEA.
DISCUSSION
Our data demonstrate favorable 30-day and long-term
outcomes after CEA and conﬁrm the long-term strokeprevention accorded by CEA. The 30-day combined
stroke/death rate after 3014 CEAs performed at our insti-
tution was 2.2%. The North American Symptomatic
Carotid Endarterectomy Trial (NASCET) study reported
30-day stroke and mortality rates of 5.5% and 0.6%, respec-
tively, with a combined stroke/death rate of 5.8%.1 In the
Asymptomatic Carotid Atherosclerosis Study (ACAS), the
combined 30-day stroke/death rate was 2.3%,4 whereas
the Asymptomatic Carotid Surgery Trial (ACST) reported
a combined 30-day stroke/death rate of 3.1%.5 Our results
show a 30-day stroke/death rate similar to the ACAS/
ACST studies even though one-third of the patients were
symptomatic upon presentation wherein perioperative
events occur more frequently.11 Indeed, our present study
also conﬁrms the effect of the patients’ symptom status on
periprocedural complications (Table II). In addition, our
study included octogenarians as well as those with comor-
bidities that would have excluded them from entering
ACAS.
Such favorable results from institutional series, how-
ever, have been questioned before. Vociferous advocates
of carotid artery stenting (CAS) were eager to dismiss the
reported results of CEA as “too good to be true,”12 and
surgeon-reported outcomes after CEA have often been
criticized for apparently under-reporting complications.13
Yet, independently adjudicated registries, such as the
National Surgical Quality Improvement Program (NSQIP),
Fig 3. Kaplan-Meier estimate for overall survival after carotid
endarterectomy (CEA) stratiﬁed by symptom status. The P value
was determined by Mantel-Cox log-rank univariate analysis.
Years 0 2 4 6 8 10 12 14
Symptomatic
At risk 1008 882 753 648 495 372 283 202
SE 0 1 1 1 1 2 2 2
Asymptomatic
At risk 2004 1814 1584 1331 967 670 504 310
SE 0 0.6 0.9 1 1 1 1 1
Table III. Independent risk factors associated with long-
term any stroke, ipsilateral stroke, reintervention, and
death using Cox proportional hazards regression
Variable HR (95% CI) Pa
Any stroke
Diabetes mellitus 1.94 (1.44-2.60) <.0001
Symptomatic disease 1.75 (1.33-2.30) <.0001
Female gender 1.34 (1.02-1.77) .0346
Age 1.02 (1.00-1.03) .0310
Ipsilateral stroke
Contralateral occlusion 2.06 (1.09-3.87) .0252
Symptomatic disease 1.87 (1.23-2.84) .0033
Lipid-lowering therapyb 0.65 (0.42-0.99) .0493
Death
COPD 1.60 (1.42-1.82) <.0001
Diabetes mellitus 1.60 (1.44-1.77) <.0001
Coronary artery disease 1.42 (1.29-1.56) <.0001
Age 1.06 (1.05-1.07) <.0001
Female gender 0.89 (0.81-0.98) .0162
Antilipid treatment 0.69 (0.63-0.76) <.0001
Reintervention
Primary closure 1.72 (1.16-2.54) .0065
Age 0.96 (0.94-0.99) .0011
CI, Conﬁdence interval; COPD, chronic obstructive pulmonary disease;
HR, hazard ratio.
aAll P values are signiﬁcant (P < .05).
bIncludes statin and nonstatin therapy.
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Carotid Endarterectomy vs Stenting Trial (CREST), have
reported outcomes quite similar to our own. We previously
reported a 30-day combined stroke/death rate of 2.2%
(identical to that reported here) after 3949 CEAs per-
formed in private-sector hospitals, using the NSQIP data-
base, which reports independently adjudicated 30-day
outcomes.14 This report also indicated similar results
among the Stenting with Angioplasty and Protection in
Patients at High Risk for Endarterectomy (SAPHIRE)
high-risk patients, including nearly 1000 octogenarian
patients who had undergone CEA. The CEA arm of
CREST likewise reported similar perioperative results
with an ipsilateral stroke rate of 1.7%.11,15 Finally, the
CREST investigators have emphasized the importance
and effect of periprocedural stroke after carotid interven-
tions. Even though most strokes after both CEA and
CAS are minor, the 4-year mortality in such patients is
increased threefold.16 The favorable outcomes after CEA
in these contemporary series, including our own, call into
question the 6% (symptomatic) and 3% (asymptomatic)
complication thresholds after carotid interventions; current
data indicate these thresholds are outdated.17-20
In addition to the symptomatic status, contralateral
carotid occlusion was an important predictor of periopera-
tive stroke at 30 days. Prior studies, including NASCET
and ACAS, in addition to more contemporary registrydata,21-25 have also identiﬁed contralateral carotid occlu-
sion as a risk factor for stroke after CEA. In a recent study
using the Society for Vascular Surgery Registry, Ricotta
et al25 reported a lower rate of periprocedural complica-
tions (death, stroke, and myocardial infarction) after CEA
compared with CAS among patients with no contralateral
occlusion. However, the beneﬁt of CEA was lost in those
patients with contralateral carotid occlusion. The loss in
beneﬁt was due to the increase in the postoperative stroke
rate after CEA among those with contralateral occlusion.
Ultimately, the effect on clinical decision making of
contralateral occlusion cannot be deﬁnitively stated.
Clearly, its effect on the results of CEA is a product of
a large data set accumulated over many years in different
types of studies. These types of data are not yet available
for CAS; furthermore, the preponderance of data on the
increased risk of stroke with CAS vs CEA mitigate a conclu-
sion that CAS might be preferable to CEA in patients with
contralateral occlusion.26
Long-term outcomes as reported here compare well
with previously reported results from randomized
controlled trials and single-center series. Our overall
5-year and 10-year survival after CEA was 70.1% and
42.2%, respectively, which is similar to our previously re-
ported outcomes (5-year survival of 72% and 10-year
survival of 45%).10 Archie et al9 reported an overall survival
of 87% at 5 years and 69% at 10 years in their series of
1360 CEAs. Such favorable 10-year survival may be an
outlier, because other large studies have reported rates
similar to the current series.7,8 Using the Swedish vascular
registry, Kragsterman et al27 reported an overall survival of
JOURNAL OF VASCULAR SURGERY
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who underwent CEA for asymptomatic disease. For those
who underwent CEA for symptomatic disease, the same
study showed 5-year and 10-year overall survival of 81.1%
and 53.8%, respectively, with no statistically signiﬁcant differ-
ence between the asymptomatic vs symptomatic patients.
Long-term stroke prevention is the ultimate goal of
intervention for carotid stenosis. The 5-year and 10-year
ipsilateral stroke-free survival was 97.6% and 94.6%, respec-
tively, in our series. The ACAS study reported 5-year ipsi-
lateral stroke-free survival of 94.9%,4 and the CEA arm of
the CREST trial reported 4-year ipsilateral stroke-free
survival of 96%.15 Our overall stroke-free survival rates
(94% at 5 years and 87% at 10 years) also compare well
with results from previous studies. Perhaps the best long-
term data on stroke prevention with CEA in asymptomatic
patients emanates from ACST, where stroke-free survival
was 89% at 10 years in patients treated with CEA vs
medical therapy.16 The corresponding 87% ﬁgure from
our data is nearly identical, with the provision that our
study was inclusive of symptomatic patients (w30%), and
we have demonstrated that symptom status at the time of
surgery is an important correlate of late stroke risk.
Antilipid treatment improved overall and ipsilateral
stroke-free survival in our study. Meta-analyses and
randomized controlled trials have previously shown that
statins improve survival and reduce the risk of initial and
recurrent stroke.28-30 The Stroke Prevention by Aggressive
Reduction in Cholesterol Levels (SPARCL) trial, for
example, showed that atorvastatin was associated with
a reduction in fatal or nonfatal stroke, with absolute risk
reduction of 2.2% at 5 years and a reduction in all coronary
events.29 We have previously reported on the protective
role of lipid-lowering drugs for both early (<2 years) and
late (>2 years) recurrent stenosis.31
Female gender was predictive of long-term stroke, and
this is in line with subanalyses of previous randomized
controlled trials for symptomatic32,33 and asymptomatic
patients34 undergoing CEA. The risk of reintervention
was increased with primary closure in our study. Primary
closure has been shown to be associated with recurrent
stenosis in previous studies,35,36 and this resulted in
a decreased rate of primary closure performed in our insti-
tution during the study period of 57.7% during the ﬁrst
5 years of the study vs 14.5% during the last 5 years of
the study.
The study is limited by its retrospective nature and
potential for referral bias given the catchment of a single
institution. Postoperative events were largely determined
from record reviews and, in that sense, lack independent
adjudication. However, the results of the current study
are similar to those of recent trials with adjudicated
outcomes in the setting of randomized controlled trials
and large prospectively gathered database.11,16
CONCLUSIONS
CEA has favorable perioperative and long-term clini-
cal and anatomic outcomes and remains the standardtreatment in stroke prevention for symptomatic and asymp-
tomatic patients with carotid stenosis. Improvements in
medical therapy (statins) have increased overall and ipsilat-
eral stroke-free survival.
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